Echinocandin Dosing for Candida rugosa
For invasive Candida rugosa infection in adults, use standard echinocandin dosing: anidulafungin 200 mg loading dose then 100 mg daily, caspofungin 70 mg loading dose then 50 mg daily, or micafungin 100 mg daily, with no adjustments needed for renal impairment and only caspofungin requiring dose reduction (to 35 mg daily) in moderate hepatic impairment.
Rationale and Dosing Details
The IDSA guidelines provide clear echinocandin dosing recommendations for invasive candidiasis that apply to all Candida species, including the less common C. rugosa 1, 2. While C. rugosa is not specifically mentioned in guidelines (as it represents <1% of invasive candidiasis cases), the standard echinocandin dosing applies:
Standard Adult Dosing
- Anidulafungin: 200 mg IV loading dose on day 1, then 100 mg IV daily 1
- Caspofungin: 70 mg IV loading dose on day 1, then 50 mg IV daily 1
- Micafungin: 100 mg IV daily (no loading dose required) 1
Adjustments for Organ Dysfunction
Renal impairment: No dose adjustment needed for any echinocandin 3, 4. All three agents can be used at standard doses regardless of creatinine clearance, including in dialysis patients.
Hepatic impairment:
- Caspofungin only: Reduce maintenance dose from 50 mg to 35 mg daily in moderate hepatic insufficiency (Child-Pugh score 7-9) 3, 4
- Anidulafungin and micafungin: No adjustment needed for any degree of hepatic impairment 3, 4
Special Populations
Critically ill patients: Standard dosing applies. Anidulafungin has the most predictable pharmacokinetics as it undergoes chemical degradation rather than hepatic metabolism 3.
Obesity: No routine dose adjustment recommended based on current evidence, though therapeutic drug monitoring may be considered in morbidly obese patients if available 5, 6.
Elderly patients: No dose adjustment required 6.
Clinical Context for C. rugosa
C. rugosa is intrinsically resistant to fluconazole and often has reduced susceptibility to other azoles, making echinocandins the preferred first-line therapy. The species typically shows good susceptibility to echinocandins, though MIC data are limited given its rarity.
Duration and Monitoring
Continue therapy for 2 weeks after documented bloodstream clearance and resolution of symptoms 1, 2. Obtain follow-up blood cultures daily or every other day until clearance is documented. Remove central venous catheters when feasible 2.
Important Caveats
Drug interactions: Caspofungin requires dose increase to 70 mg daily if co-administered with rifampin or other enzyme inducers; anidulafungin and micafungin have minimal drug interactions 3, 4. Anidulafungin has the lowest potential for drug-drug interactions among the three agents.
Therapeutic drug monitoring: Consider for echinocandins in critically ill patients with altered volume of distribution, severe hypoalbuminemia, or extracorporeal circuits, targeting trough levels >1 mg/L if available 5.